These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
144 related articles for article (PubMed ID: 35574418)
1. Tumor Suppressive Role of MUC6 in Wilms Tumor Liu BH; Liu GB; Zhang BB; Shen J; Xie LL; Liu XQ; Yao W; Dong R; Bi YL; Dong KR Front Oncol; 2022; 12():756117. PubMed ID: 35574418 [TBL] [Abstract][Full Text] [Related]
2. Upregulation of Wilms' tumor gene 1 (WT1) in desmoid tumors. Amini Nik S; Hohenstein P; Jadidizadeh A; Van Dam K; Bastidas A; Berry RL; Patek CE; Van der Schueren B; Cassiman JJ; Tejpar S Int J Cancer; 2005 Mar; 114(2):202-8. PubMed ID: 15540161 [TBL] [Abstract][Full Text] [Related]
3. Activation of the Wnt/β-catenin pathway is common in wilms tumor, but rarely through β-catenin mutation and APC promoter methylation. Schweigert A; Fischer C; Mayr D; von Schweinitz D; Kappler R; Hubertus J Pediatr Surg Int; 2016 Dec; 32(12):1141-1146. PubMed ID: 27679509 [TBL] [Abstract][Full Text] [Related]
4. [Effect of LncRNA HOTAIR on the proliferation, apoptosis and drug resistance of Wilms tumor cells through Wnt/β-catenin signaling pathway]. Yang LL; Cao GH; Liu YJ; Liu CH Zhonghua Zhong Liu Za Zhi; 2021 Jul; 43(7):769-774. PubMed ID: 34289571 [No Abstract] [Full Text] [Related]
5. Frequent association of beta-catenin and WT1 mutations in Wilms tumors. Maiti S; Alam R; Amos CI; Huff V Cancer Res; 2000 Nov; 60(22):6288-92. PubMed ID: 11103785 [TBL] [Abstract][Full Text] [Related]
6. Codon 45 of the beta-catenin gene, a specific mutational target site of Wilms' tumor. Kusafuka T; Miao J; Kuroda S; Udatsu Y; Yoneda A Int J Mol Med; 2002 Oct; 10(4):395-9. PubMed ID: 12239584 [TBL] [Abstract][Full Text] [Related]
7. Long non-coding RNA LINP1 induces tumorigenesis of Wilms' tumor by affecting Wnt/β-catenin signaling pathway. Zhu KR; Sun QF; Zhang YQ Eur Rev Med Pharmacol Sci; 2019 Jul; 23(13):5691-5698. PubMed ID: 31298321 [TBL] [Abstract][Full Text] [Related]
8. Target genes of the WNT/beta-catenin pathway in Wilms tumors. Zirn B; Samans B; Wittmann S; Pietsch T; Leuschner I; Graf N; Gessler M Genes Chromosomes Cancer; 2006 Jun; 45(6):565-74. PubMed ID: 16575872 [TBL] [Abstract][Full Text] [Related]
9. Wilms tumor genetics: mutations in WT1, WTX, and CTNNB1 account for only about one-third of tumors. Ruteshouser EC; Robinson SM; Huff V Genes Chromosomes Cancer; 2008 Jun; 47(6):461-70. PubMed ID: 18311776 [TBL] [Abstract][Full Text] [Related]
10. CTNNB1 mutations and overexpression of Wnt/beta-catenin target genes in WT1-mutant Wilms' tumors. Li CM; Kim CE; Margolin AA; Guo M; Zhu J; Mason JM; Hensle TW; Murty VV; Grundy PE; Fearon ER; D'Agati V; Licht JD; Tycko B Am J Pathol; 2004 Dec; 165(6):1943-53. PubMed ID: 15579438 [TBL] [Abstract][Full Text] [Related]
11. Nuclear accumulation of beta-catenin protein in Wilms' tumours. Koesters R; Niggli F; von Knebel Doeberitz M; Stallmach T J Pathol; 2003 Jan; 199(1):68-76. PubMed ID: 12474228 [TBL] [Abstract][Full Text] [Related]
12. Beta-catenin expression and mutation in adult and pediatric Wilms' tumors. Su MC; Huang WC; Lien HC APMIS; 2008 Sep; 116(9):771-8. PubMed ID: 19024596 [TBL] [Abstract][Full Text] [Related]
13. Immunohistochemical expression profiles of mucin antigens in salivary gland mucoepidermoid carcinoma: MUC4- and MUC6-negative expression predicts a shortened survival in the early postoperative phase. Honjo K; Hiraki T; Higashi M; Noguchi H; Nomoto M; Yoshimura T; Batra SK; Yonezawa S; Semba I; Nakamura N; Tanimoto A; Yamada S Histol Histopathol; 2018 Feb; 33(2):201-213. PubMed ID: 28649694 [TBL] [Abstract][Full Text] [Related]
14. LncRNA MEG3 inhibits the growth, invasion and migration of Wilms' tumor via Wnt/β-catenin pathway. Teng GY; Wang YJ; Geng M; Jiang ZP Eur Rev Med Pharmacol Sci; 2020 Oct; 24(19):9899-9907. PubMed ID: 33090393 [TBL] [Abstract][Full Text] [Related]
15. Functional KRAS mutations and a potential role for PI3K/AKT activation in Wilms tumors. Polosukhina D; Love HD; Correa H; Su Z; Dahlman KB; Pao W; Moses HL; Arteaga CL; Lovvorn HN; Zent R; Clark PE Mol Oncol; 2017 Apr; 11(4):405-421. PubMed ID: 28188683 [TBL] [Abstract][Full Text] [Related]
16. Nephroblastoma (Wilms' tumor): a model system of aberrant renal development. Re GG; Hazen-Martin DJ; Sens DA; Garvin AJ Semin Diagn Pathol; 1994 May; 11(2):126-35. PubMed ID: 7809506 [TBL] [Abstract][Full Text] [Related]
17. Sequential WT1 and CTNNB1 mutations and alterations of beta-catenin localisation in intralobar nephrogenic rests and associated Wilms tumours: two case studies. Fukuzawa R; Heathcott RW; More HE; Reeve AE J Clin Pathol; 2007 Sep; 60(9):1013-6. PubMed ID: 17172473 [TBL] [Abstract][Full Text] [Related]
18. Expression of TCF3 in Wilms' tumor and its regulatory role in kidney tumor cell viability, migration and apoptosis Zhou N; Yan B; Ma J; Jiang H; Li L; Tang H; Ji F; Yao Z Mol Med Rep; 2021 Sep; 24(3):. PubMed ID: 34278464 [TBL] [Abstract][Full Text] [Related]
19. Diffuse expression of MUC6 defines a distinct clinicopathological subset of pulmonary invasive mucinous adenocarcinoma. Kishikawa S; Hayashi T; Saito T; Takamochi K; Kohsaka S; Sano K; Sasahara N; Sasa K; Kurihara T; Hara K; Suehara Y; Takahashi F; Suzuki K; Yao T Mod Pathol; 2021 Apr; 34(4):786-797. PubMed ID: 33024306 [TBL] [Abstract][Full Text] [Related]